Hyperthermia Blog

News and Opinions About Our Industry

The University Hospital Campus Bio-Medico Rome announced the opening of its new thermal oncology unit with the acquisition of two new Linacs and two new hyperthermia treatment systems.  The hospital chose the Pyrexar BSD-500 Superficial/Interstitial System and a BSD-2000 Deep Regional Hyperthermia System to improve cancer treatment. In an article published in the Corriere Della Sera, the hospital shared the following reasons for investing in hyperthermia, a vital cancer treatment technology.

  • tumor oxygenation
  • inhibition of DNA repair
  • anti-tumor immune response
  • enhanced efficacy
  • low toxicity
  • painless and non-invasive

biomedico italy 2000 2a

A special thanks to our distributor, Tema Sinergie, for their excellent representation and continuing efforts in expanding hyperthermia throughout Italy.